Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial
| Autor: | Didier Hans, Enisa Shevroja, Jose R. Zanchetta, Lorraine A. Fitzpatrick, Gary Hattersley, Benjamin Z. Leder, J. P. Bilezikian, K. Banks, Alan G. Harris |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Bone density Injections Subcutaneous Endocrinology Diabetes and Metabolism Abaloparatide Anabolics Bone microarchitecture Clinical trials Osteoporosis Urology 030209 endocrinology & metabolism Lumbar vertebrae 03 medical and health sciences Absorptiometry Photon 0302 clinical medicine Trabecular bone score Double-Blind Method Bone Density Teriparatide medicine Humans Osteoporosis Postmenopausal Aged Aged 80 and over Bone mineral Lumbar Vertebrae Bone Density Conservation Agents Dose-Response Relationship Drug business.industry Parathyroid Hormone-Related Protein Middle Aged medicine.disease 030104 developmental biology medicine.anatomical_structure Cancellous Bone Original Article Female business Cancellous bone Osteoporotic Fractures medicine.drug |
| Zdroj: | Osteoporosis international, vol. 29, no. 2, pp. 323-328 Osteoporosis International |
| Popis: | Summary In a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to one of three different doses of abaloparatide-SC, subcutaneous teriparatide, or placebo for 24 weeks, abaloparatide-SC resulted in improvements in skeletal microarchitecture as measured by the trabecular bone score. Introduction Subcutaneous abaloparatide (abaloparatide-SC) increases total hip and lumbar spine bone mineral density and reduces vertebral and non-vertebral fractures. In this study, we analyzed the extent to which abaloparatide-SC improves skeletal microarchitecture, assessed indirectly by trabecular bone score (TBS). Methods This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks. TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible. Assessments were made at baseline, 12 and 24 weeks. Between-group differences were assessed by generalized estimating equations adjusted for relevant baseline characteristics, and a pre-determined least significant change analysis was performed. Results After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|